Algorx Pharmaceuticals Inc (NASDAQ:AGRX) Institutional Investor Sentiment Trend

September 16, 2018 - By Margaret Guttierez

Agile Therapeutics, Inc. (NASDAQ:AGRX) Logo

Sentiment for Algorx Pharmaceuticals Inc (NASDAQ:AGRX)

Algorx Pharmaceuticals Inc (NASDAQ:AGRX) institutional sentiment decreased to 0.7 in 2018 Q2. Its down -0.42, from 1.12 in 2018Q1. The ratio is negative, as 14 funds increased and started new stock positions, while 20 sold and decreased stakes in Algorx Pharmaceuticals Inc. The funds in our partner’s database now hold: 15.95 million shares, down from 23.01 million shares in 2018Q1. Also, the number of funds holding Algorx Pharmaceuticals Inc in their top 10 stock positions decreased from 4 to 2 for a decrease of 2. Sold All: 12 Reduced: 8 Increased: 8 New Position: 6.

Agile Therapeutics, Inc., a forward-thinking women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. The company has market cap of $12.45 million. The Company’s lead product candidate is Twirla, also known as AG200-15, a once-weekly contraceptive patch, which completed Phase III clinical trials. It currently has negative earnings. The firm is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

The stock decreased 25.36% or $0.123 during the last trading session, reaching $0.362. About 5.79M shares traded or 266.23% up from the average. Agile Therapeutics, Inc. (NASDAQ:AGRX) has declined 84.42% since September 16, 2017 and is downtrending. It has underperformed by 100.04% the S&P500.

Analysts await Agile Therapeutics, Inc. (NASDAQ:AGRX) to report earnings on November, 5. They expect $-0.16 earnings per share, up 27.27 % or $0.06 from last year’s $-0.22 per share. After $-0.16 actual earnings per share reported by Agile Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Proquest Associates Iv Llc holds 3.85% of its portfolio in Agile Therapeutics, Inc. for 5.06 million shares. Investor Ab owns 3.51 million shares or 0.09% of their US portfolio. Moreover, Perceptive Advisors Llc has 0.05% invested in the company for 3.53 million shares. The New York-based Needham Investment Management Llc has invested 0.03% in the stock. Acadian Asset Management Llc, a Massachusetts-based fund reported 86,792 shares.

Agile Therapeutics, Inc. (NASDAQ:AGRX) Ratings Coverage

Ratings analysis reveals 100% of Agile Therapeutics’s analysts are positive. Out of 2 Wall Street analysts rating Agile Therapeutics, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $400 while the high is $800. The stock’s average target of $6 is 1557.46% above today’s ($0.362) share price. AGRX was included in 3 notes of analysts from March 29, 2018. The firm earned “Buy” rating on Wednesday, May 9 by H.C. Wainwright. Cantor Fitzgerald maintained Agile Therapeutics, Inc. (NASDAQ:AGRX) on Thursday, March 29 with “Buy” rating. Cantor Fitzgerald maintained Agile Therapeutics, Inc. (NASDAQ:AGRX) on Tuesday, May 8 with “Buy” rating.

More news for Agile Therapeutics, Inc. (NASDAQ:AGRX) were recently published by: Benzinga.com, which released: “48 Biggest Movers From Yesterday” on September 12, 2018. Seekingalpha.com‘s article titled: “Agile Therapeutics up 55% premarket” and published on September 11, 2018 is yet another important article.

Agile Therapeutics, Inc. (NASDAQ:AGRX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.